Status:
COMPLETED
Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadm...
Eligibility Criteria
Inclusion
- Mixed dyslipidemia
Exclusion
- Diabetes,
- Known hypersensitivity to fenofibrate or simvastatin,
- Pregnant or lactating women,
- Contra-indication to fenofibrate or simvastatin,
- Unstable or severe cardiac disease.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00352183
Start Date
January 1 2006
End Date
August 1 2008
Last Update
July 8 2009
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 204
Adelaide, Australia
2
Site 214
Adelaide, Australia
3
Site 203
Bendigo, Australia
4
Site 207
Brisbane, Australia